Correlation of SIDT1 with Poor Prognosis and Immune Infiltration in Patients with Non-Small Cell Lung Cancer

References

• Cao M, Chen W. Epidemiology of lung cancer in China. Thorac Cancer. 2019;10(1):3–7. doi:10.1111/1759-7714.12916
   PubMed Web of Science ®Google Scholar
• Chen WQ, Li H, Sun KX, et al. [Report of Cancer Incidence and Mortality in China, 2014]. Zhonghua Zhong Liu Za Zhi. 2018;40(1):5–13. Chinese. doi:10.3760/cma.j.issn.0253-3766.2018.01.002
   PubMedGoogle Scholar
• Winston WM, Molodowitch C, Hunter CP. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science. 2002;295(5564):2456–2459. doi:10.1126/science.1068836
   PubMed Web of Science ®Google Scholar
• Wang Y, Li H, Ma J, et al. Integrated bioinformatics data analysis reveals prognostic significance of SIDT1 in triple-negative breast cancer. Onco Targets Ther. 2019;12:8401–8410. doi:10.2147/OTT.S215898
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhang F, Dong L, et al. SIDT1-dependent absorption in the stomach mediates host uptake of dietary and orally administered microRNAs. Cell Res. 2021;31(3):247–258. doi:10.1038/s41422-020-0389-3
   PubMed Web of Science ®Google Scholar
• Gao ZJ, Wang Y, Yuan WD, Yuan JQ, Yuan K. HIF-2alpha not HIF-1alpha overexpression confers poor prognosis in non-small cell lung cancer. Tumour Biol. 2017;39(6):1010428317709637. doi:10.1177/1010428317709637
   Google Scholar
• Lee KM, Guerrero-Zotano AL, Servetto A, et al. Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nat Commun. 2020;11(1):5488. doi:10.1038/s41467-020-19291-x
   PubMed Web of Science ®Google Scholar
• Shen H, Wang Z, Ren S, et al. Prognostic biomarker MITD1 and its correlation with immune infiltrates in hepatocellular carcinoma (HCC). Int Immunopharmacol. 2020;81:106222. doi:10.1016/j.intimp.2020.106222
   PubMed Web of Science ®Google Scholar
• Zhao R, Peng C, Song C, et al. BICC1 as a novel prognostic biomarker in gastric cancer correlating with immune infiltrates. Int Immunopharmacol. 2020;87:106828. doi:10.1016/j.intimp.2020.106828
   PubMed Web of Science ®Google Scholar
• Gu Y, Li X, Bi Y, et al. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY). 2020;12(1):784–807. doi:10.18632/aging.102656
   PubMedGoogle Scholar
• Xu H, Yu S, Yuan X, et al. DACH1 suppresses breast cancer as a negative regulator of CD44. Sci Rep. 2017;7(1):4361. doi:10.1038/s41598-017-04709-2
   PubMed Web of Science ®Google Scholar
• Sun J, Xie T, Jamal M, et al. CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment. Cancer Cell Int. 2020;20:106. doi:10.1186/s12935-020-01183-1
   PubMed Web of Science ®Google Scholar
• Wu Y, Lin Y, Pan J, et al. NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway. Cancer Cell Int. 2021;21(1):443. doi:10.1186/s12935-021-02138-w
   PubMed Web of Science ®Google Scholar
• Chen J, Wang Z, Wang W, et al. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: a study based on TCGA data. Int Immunopharmacol. 2020;84:106490. doi:10.1016/j.intimp.2020.106490
   PubMed Web of Science ®Google Scholar
• Chen Q, Pu N, Yin H, et al. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. J Cell Mol Med. 2020;24(15):8674–8686. doi:10.1111/jcmm.15500
   PubMed Web of Science ®Google Scholar
• Geng Q, Shen Z, Li L, Zhao J. COL1A1 is a prognostic biomarker and correlated with immune infiltrates in lung cancer. PeerJ. 2021;9:e11145. doi:10.7717/peerj.11145
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.0000000000000630
   PubMed Web of Science ®Google Scholar
• Elhassan MO, Christie J, Duxbury MS. Homo sapiens systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) protein mediates contact-dependent small RNA transfer and microRNA-21-driven chemoresistance. J Biol Chem. 2012;287(8):5267–5277. doi:10.1074/jbc.M111.318865
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Li BH, Yang XZ, et al. IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine. 2008;42(1):39–47. doi:10.1016/j.cyto.2008.01.016
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25(10):1149–1157. doi:10.1038/nbt1339
   PubMed Web of Science ®Google Scholar
• Mendez-Acevedo KM, Valdes VJ, Asanov A, Vaca L. A novel family of mammalian transmembrane proteins involved in cholesterol transport. Sci Rep. 2017;7(1):7450. doi:10.1038/s41598-017-07077-z
   PubMed Web of Science ®Google Scholar
• Liu J, Han X, Chen L, et al. is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma. Aging (Albany NY). 2020;12(20):20308–20331. doi:10.18632/aging.103804
   PubMedGoogle Scholar
• Sui S, An X, Xu C, et al. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics. 2020;10(26):11938–11949. doi:10.7150/thno.49451
   PubMed Web of Science ®Google Scholar
• Vahl JC, Drees C, Heger K, et al. Continuous T cell receptor signals maintain a functional regulatory T cell pool. Immunity. 2014;41(5):722–736. doi:10.1016/j.immuni.2014.10.012
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao X, Xiao H, et al. APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC. BMC Cancer. 2021;21(1):233. doi:10.1186/s12885-021-07950-1
   PubMed Web of Science ®Google Scholar
• Donnem T, Hald S, Paulsen E, et al. Stromal CD8+ T-cell density—a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2635–2643. doi:10.1158/1078-0432.Ccr-14-1905
   PubMed Web of Science ®Google Scholar
• Xiao Z, Hu L, Yang L, et al. TGFβ2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer. J Cell Mol Med. 2020;24(13):7151–7162. doi:10.1111/jcmm.15164
   PubMed Web of Science ®Google Scholar